RecruitingNot ApplicableNCT04699864

Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

The Use of Artificial Intelligence in the Early Detection and the Follow-Up of Diabetic Retinopathy of Diabetic Patients Followed at the CHUM: Evaluation of NeoRetina Automated Algorithm (DIAGNOS Inc.)

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

630 participants

Start Date

Jun 10, 2024

Study Type

INTERVENTIONAL

Conditions

Diabetic Retinopathy Diabetic Macular Edema Diabetic Maculopathy

Summary

This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating an artificial intelligence tool called NeoRetina, which analyzes photos of the back of the eye (retinal images) to screen for diabetic eye disease (diabetic retinopathy). Researchers want to see if this AI system is as accurate as traditional specialist review. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Type 1 diabetes (for at least 5 years) or Type 2 diabetes - You are currently followed by an endocrinologist at the CHUM hospital, are hospitalized there, or are on the ophthalmology waiting list at CHUM **You may NOT be eligible if...** - You do not have diabetes - You are unable to provide informed consent - You are not a patient at the CHUM hospital system Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTScreening of DR and DME with artificial intelligence using NeoRetina

Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.

DIAGNOSTIC_TESTRoutine ophthalmological evaluation of DR and DME

Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.

DIAGNOSTIC_TESTManual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos

Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.

Locations(1)

Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04699864

Related Trials

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

NCT074891311 location

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

NCT036807941 location

Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice

NCT070150342 locations

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

NCT074255228 locations

Defining Retinal Structures Using Hyperspectral Retinal Imaging

NCT075555741 location